A 32-year-old man with a history of giant cell tumor of the distal femur treated with intralesional curettage and bone grafting 3 years ago now presents with a recurrent lytic lesion at the same site. Imaging shows local recurrence without distant metastases. He is counseled about treatment options. Which of the following is the most appropriate next step in management?

Explanation

## Management of Recurrent Giant Cell Tumor ### Treatment Algorithm for GCT Recurrence For a **first recurrence** of giant cell tumor (GCT) that is locally contained (no soft tissue extension, no cortical breakthrough, no distant metastases), the standard of care remains **repeat intralesional curettage with adjuvant therapy** (phenol, hydrogen peroxide, or argon beam coagulation) combined with **cement (PMMA) packing**. **High-Yield:** According to Campanacci's classification and current orthopedic oncology guidelines (Campbell's Operative Orthopaedics; Unni & Inwards, Dahlin's Bone Tumors), repeat curettage with adjuvants is the preferred first-line approach for recurrent, contained GCT because: 1. It preserves joint function and avoids the morbidity of wide excision. 2. Phenol acts as a chemical adjuvant that extends the effective surgical margin. 3. PMMA cement packing provides structural support and generates exothermic heat that further destroys residual tumor cells. ### Why Denosumab Is NOT the First-Line for This Scenario **Clinical Pearl:** Denosumab (RANKL inhibitor) is indicated for: - **Unresectable** GCT (e.g., sacral, spinal, or pelvic lesions not amenable to surgery) - **Neoadjuvant** use before surgery in aggressive/extensive recurrences with soft tissue involvement - **Metastatic** GCT (pulmonary metastases) - Multiple recurrences where repeat curettage is no longer feasible In this vignette, the recurrence is **local, without distant metastases**, and the site (distal femur) is surgically accessible — making repeat curettage with adjuvants the most appropriate next step, not denosumab as a primary intervention. ### Why Wide Excision Is Suboptimal Here Wide excision with endoprosthetic reconstruction (Option D) is reserved for: - Multiple recurrences after failed curettage - Extensive bone destruction precluding joint salvage - Aggressive lesions with uncontrolled soft tissue extension It carries significant functional morbidity and is not the first choice for a first recurrence at the distal femur. ### Comparison of Management Strategies | Approach | Indication | Recurrence Risk | Morbidity | | --- | --- | --- | --- | | **Repeat curettage + adjuvants** | First/second recurrence, contained | 20–40% | Low | | **Denosumab ± surgery** | Unresectable, aggressive, metastatic | Variable | Low–Moderate | | **Wide excision** | Multiple recurrences, uncontrolled | <5% | High (functional loss) | | **Observation** | Asymptomatic, stable (rarely appropriate) | High | Variable | **Key Point:** Observation (Option C) is inappropriate for a confirmed, enlarging recurrent GCT — the tumor will progress and become harder to control. **Reference:** Campbell's Operative Orthopaedics, 14th ed.; Unni & Inwards, Dahlin's Bone Tumors, 6th ed.; NCCAP/ESMO guidelines on bone sarcomas. **Mnemonic:** For GCT recurrence — **"Curette first, escalate later"** — repeat curettage with adjuvants before resorting to denosumab or wide excision.